Seres Therapeutics Company Profile (NASDAQ:MCRB)

About Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics logoSeres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MCRB
  • CUSIP: N/A
  • Web: www.serestherapeutics.com
Capitalization:
  • Market Cap: $651.84 million
  • Outstanding Shares: 40,513,000
Average Prices:
  • 50 Day Moving Avg: $14.64
  • 200 Day Moving Avg: $14.64
  • 52 Week Range: $8.86 - $16.60
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.59
  • P/E Growth: -0.12
Sales & Book Value:
  • Annual Revenue: $22.08 million
  • Price / Sales: 29.52
  • Book Value: $2.18 per share
  • Price / Book: 7.38
Profitability:
  • EBIDTA: ($92,650,000.00)
  • Net Margins: -441.38%
  • Return on Equity: -80.21%
  • Return on Assets: -37.80%
Debt:
  • Debt-to-Equity Ratio: 0.11%
  • Current Ratio: 6.86%
  • Quick Ratio: 6.86%
Misc:
  • Average Volume: 152,057 shs.
  • Beta: 0.29
  • Short Ratio: 14.18
 

Frequently Asked Questions for Seres Therapeutics (NASDAQ:MCRB)

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) released its earnings results on Thursday, August, 3rd. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by $0.10. The business earned $3 million during the quarter, compared to the consensus estimate of $3 million. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The firm's revenue for the quarter was up .0% on a year-over-year basis. During the same period last year, the business posted ($0.70) EPS. View Seres Therapeutics' Earnings History.

When will Seres Therapeutics make its next earnings announcement?

Seres Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Seres Therapeutics.

Where is Seres Therapeutics' stock going? Where will Seres Therapeutics' stock price be in 2017?

5 brokerages have issued twelve-month price targets for Seres Therapeutics' stock. Their predictions range from $16.00 to $20.00. On average, they expect Seres Therapeutics' stock price to reach $18.25 in the next twelve months. View Analyst Ratings for Seres Therapeutics.

What are analysts saying about Seres Therapeutics stock?

Here are some recent quotes from research analysts about Seres Therapeutics stock:

  • 1. According to Zacks Investment Research, "Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (8/8/2017)
  • 2. Cowen and Company analysts commented, "We are optimistic that modifications to the clinical trial plan for SER-109 in recurrent." (5/19/2017)
  • 3. Canaccord Genuity analysts commented, "We believe that SER-109 Phase 2 trial study power was decreased by the inclusion of misdiagnosed and non-disease active patients. MCRB indicated that 72 of the 89 patients enrolled in the Phase 2 trials were chosen based on C. Difficile PCR diagnosis. A positive PCR test indicates that the cytotoxin gene is present, but does not directly indicate that the C. Difficile bacterium is producing the cytotoxin that causes the underlying symptoms. Thus a direct testing of cytotoxin is the most indicative of disease activity, and further qualifying stool samples analysis showed that only 15 of 31 PCR- positive samples were cytotoxin-positive. Importantly, Optimer utilized toxin testing for its fidaxomicin clinical program for recurrent C." (1/31/2017)

Who are some of Seres Therapeutics' key competitors?

Who are Seres Therapeutics' key executives?

Seres Therapeutics' management team includes the folowing people:

  • Roger Pomerantz M.D., Chairman of the Board, President, Chief Executive Officer
  • Eric D. Shaff, Chief Financial Officer, Executive Vice President
  • John G. Aunins Ph.D., Chief Technology Officer, Executive Vice President - Bioprocess and Manufacturing
  • David N. Cook Ph.D., Chief Scientific Officer, Executive Vice President - Research & Development
  • Thomas J. DesRosier J.D., Chief Legal Officer, Executive Vice President and Secretary
  • Michele Trucksis Ph.D. M.D., Chief Medical Officer and Executive Vice President
  • Noubar B. Afeyan, Lead Independent Director
  • Willard H. Dere M.D., Director
  • Dennis A. Ausiello M.D., Independent Director
  • Gregory Behar, Independent Director

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Who owns Seres Therapeutics stock?

Seres Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Flagship Pioneering Inc. (31.40%), FMR LLC (14.99%), Vanguard Group Inc. (3.92%), Capital World Investors (3.85%), ARK Investment Management LLC (1.89%) and Federated Investors Inc. PA (1.85%). Company insiders that own Seres Therapeutics stock include David N Cook, Eric D Shaff, John G Aunins, Michele Trucksis, Roger Pomerantz and Ventures Fund 2007 L Flagship. View Institutional Ownership Trends for Seres Therapeutics.

Who sold Seres Therapeutics stock? Who is selling Seres Therapeutics stock?

Seres Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., TIAA CREF Investment Management LLC, Federated Investors Inc. PA, Tudor Investment Corp ET AL, Goldman Sachs Group Inc., Wells Fargo & Company MN, Cutler Group LP and PDT Partners LLC. View Insider Buying and Selling for Seres Therapeutics.

Who bought Seres Therapeutics stock? Who is buying Seres Therapeutics stock?

Seres Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, State Street Corp, Northern Trust Corp, DekaBank Deutsche Girozentrale, Citadel Advisors LLC, Vanguard Group Inc., State of Wisconsin Investment Board and Dimensional Fund Advisors LP. View Insider Buying and Selling for Seres Therapeutics.

How do I buy Seres Therapeutics stock?

Shares of Seres Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Seres Therapeutics' stock price today?

One share of Seres Therapeutics stock can currently be purchased for approximately $16.09.


MarketBeat Community Rating for Seres Therapeutics (NASDAQ MCRB)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  145 (Vote Outperform)
Underperform Votes:  111 (Vote Underperform)
Total Votes:  256
MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Seres Therapeutics (NASDAQ:MCRB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.25 (13.42% upside)

Analysts' Ratings History for Seres Therapeutics (NASDAQ:MCRB)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/30/2017Cantor FitzgeraldReiterated RatingBuyLowView Rating Details
8/4/2017HC WainwrightReiterated RatingBuy -> Buy$15.00 -> $19.00HighView Rating Details
8/3/2017Canaccord GenuitySet Price TargetBuy$20.00LowView Rating Details
5/19/2017Cowen and CompanyReiterated RatingBuyMediumView Rating Details
3/20/2017FBR & CoReiterated RatingOutperform$18.00LowView Rating Details
8/11/2016Leerink SwannReiterated RatingBuy$12.00N/AView Rating Details
8/1/2016Bank of America CorporationDowngradeBuy -> NeutralN/AView Rating Details
3/3/2016GuggenheimInitiated CoverageBuy$41.00N/AView Rating Details
2/22/2016Goldman Sachs Group, Inc. (The)Lower Price Target$35.00 -> $34.00N/AView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Seres Therapeutics (NASDAQ:MCRB)
Earnings by Quarter for Seres Therapeutics (NASDAQ:MCRB)
Earnings History by Quarter for Seres Therapeutics (NASDAQ MCRB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.39)N/AView Earnings Details
8/3/2017Q2 2017($0.59)($0.69)$3.00 million$3.00 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.65)($0.63)$3.00 million$3.02 millionViewListenView Earnings Details
3/16/2017Q4 2016($0.70)($0.63)$3.00 million$3.00 millionViewN/AView Earnings Details
11/10/2016Q316($0.55)($0.46)$10.38 million$13.02 millionViewListenView Earnings Details
8/11/2016Q216($0.46)($0.70)$4.20 million$3.00 millionViewListenView Earnings Details
5/16/2016Q116($0.48)($0.50)$1.25 million$2.71 millionViewListenView Earnings Details
11/10/2015Q315($0.32)($0.38)ViewListenView Earnings Details
8/6/2015Q215($0.30)($1.45)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Seres Therapeutics (NASDAQ:MCRB)
2017 EPS Consensus Estimate: ($2.34)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.73)($0.53)($0.63)
Q2 20172($0.61)($0.50)($0.56)
Q3 20172($0.66)($0.23)($0.45)
Q4 20172($0.74)($0.68)($0.71)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Seres Therapeutics (NASDAQ:MCRB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Seres Therapeutics (NASDAQ:MCRB)
Insider Ownership Percentage: 35.70%
Institutional Ownership Percentage: 74.76%
Insider Trades by Quarter for Seres Therapeutics (NASDAQ:MCRB)
Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)
Insider Trades by Quarter for Seres Therapeutics (NASDAQ:MCRB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/29/2016John G AuninsInsiderSell9,390$10.87$102,069.30View SEC Filing  
7/28/2016Michele TrucksisInsiderSell4,156$35.18$146,208.08View SEC Filing  
7/27/2016Michele TrucksisInsiderSell38,064$35.14$1,337,568.96View SEC Filing  
7/25/2016John G AuninsInsiderSell9,390$34.18$320,950.20View SEC Filing  
7/6/2016Roger PomerantzCEOSell88,211$29.45$2,597,813.95View SEC Filing  
7/1/2016Roger PomerantzCEOSell56,789$29.81$1,692,880.09View SEC Filing  
6/30/2016Eric D ShaffCFOSell4,533$29.54$133,904.82View SEC Filing  
6/28/2016Eric D ShaffCFOSell5,001$28.28$141,428.28View SEC Filing  
6/27/2016John G AuninsEVPSell9,390$27.23$255,689.70View SEC Filing  
6/2/2016David N CookEVPSell8,000$31.00$248,000.00View SEC Filing  
6/2/2016Roger PomerantzCEOSell74,049$32.52$2,408,073.48View SEC Filing  
6/1/2016David N CookEVPSell16,000$29.43$470,880.00View SEC Filing  
6/1/2016Roger PomerantzCEOSell70,951$30.51$2,164,715.01View SEC Filing  
5/25/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell1,000,000$27.60$27,600,000.00View SEC Filing  
5/24/2016Roger PomerantzCEOSell9,801$30.00$294,030.00View SEC Filing  
5/6/2016Roger PomerantzCEOSell8,507$24.31$206,805.17View SEC Filing  
5/5/2016Roger PomerantzCEOSell59,325$26.13$1,550,162.25View SEC Filing  
5/3/2016Roger PomerantzCEOSell67,367$28.70$1,933,432.90View SEC Filing  
4/25/2016John G AuninsEVPSell18,640$31.94$595,361.60View SEC Filing  
4/7/2016David N CookEVPSell8,000$31.00$248,000.00View SEC Filing  
4/7/2016Roger PomerantzCEOSell9,212$30.00$276,360.00View SEC Filing  
4/4/2016David N CookEVPSell61,000$26.16$1,595,760.00View SEC Filing  
4/4/2016Eric D ShaffCFOSell6,568$28.85$189,486.80View SEC Filing  
4/4/2016Roger PomerantzCEOSell135,788$27.20$3,693,433.60View SEC Filing  
3/31/2016Eric D ShaffCFOSell7,663$26.30$201,536.90View SEC Filing  
3/28/2016Eric D ShaffCFOSell5,473$24.07$131,735.11View SEC Filing  
3/28/2016John G AuninsEVPSell9,390$23.89$224,327.10View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Seres Therapeutics (NASDAQ:MCRB)
Latest Headlines for Seres Therapeutics (NASDAQ:MCRB)
Source:
DateHeadline
americanbankingnews.com logoSeres Therapeutics, Inc. (MCRB) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 12 at 4:40 AM
americanbankingnews.com logo Analysts Anticipate Seres Therapeutics, Inc. (MCRB) Will Post Quarterly Sales of $23.01 Million
www.americanbankingnews.com - September 11 at 10:50 AM
americanbankingnews.com logo-$0.24 EPS Expected for Seres Therapeutics, Inc. (MCRB) This Quarter
www.americanbankingnews.com - September 9 at 11:50 AM
finance.yahoo.com logoSeres Therapeutics to Present at the Baird 2017 Global Healthcare Conference
finance.yahoo.com - September 1 at 3:52 AM
americanbankingnews.com logoSeres Therapeutics, Inc. (MCRB) Earns Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - August 31 at 7:34 PM
americanbankingnews.com logoSeres Therapeutics (MCRB) & Ophthotech Corporation (OPHT) Head to Head Comparison
www.americanbankingnews.com - August 30 at 12:22 AM
americanbankingnews.com logoZacks: Brokerages Expect Seres Therapeutics, Inc. (MCRB) Will Announce Quarterly Sales of $23.01 Million
www.americanbankingnews.com - August 23 at 9:56 AM
americanbankingnews.com logoZacks: Brokerages Expect Seres Therapeutics, Inc. (MCRB) Will Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - August 21 at 6:14 PM
americanbankingnews.com logoSeres Therapeutics, Inc. (MCRB) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - August 18 at 4:40 AM
americanbankingnews.com logoSeres Therapeutics, Inc. (NASDAQ:MCRB) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - August 13 at 9:02 AM
americanbankingnews.com logoFY2017 Earnings Forecast for Seres Therapeutics, Inc. (NASDAQ:MCRB) Issued By Cantor Fitzgerald
www.americanbankingnews.com - August 10 at 10:42 AM
americanbankingnews.com logoLeerink Swann Research Analysts Increase Earnings Estimates for Seres Therapeutics, Inc. (NASDAQ:MCRB)
www.americanbankingnews.com - August 7 at 7:40 AM
americanbankingnews.com logoSeres Therapeutics, Inc. (NASDAQ:MCRB) Expected to Post Quarterly Sales of $3.00 Million
www.americanbankingnews.com - August 5 at 7:14 AM
americanbankingnews.com logoHC Wainwright Increases Seres Therapeutics, Inc. (NASDAQ:MCRB) Price Target to $19.00
www.americanbankingnews.com - August 4 at 10:36 AM
businesswire.com logoSeres Therapeutics Reports Second Quarter 2017 Financial Results ... - Business Wire (press release)
www.businesswire.com - August 4 at 1:27 AM
finance.yahoo.com logoInvestor Network: Seres Therapeutics Inc to Host Earnings Call
finance.yahoo.com - August 4 at 1:27 AM
finance.yahoo.com logoSeres Therapeutics Reports Second Quarter 2017 Financial Results and Provides Update on Operational Progress
finance.yahoo.com - August 4 at 1:27 AM
finance.yahoo.com logoSeres Therapeutics reports 2Q loss
finance.yahoo.com - August 4 at 1:27 AM
finance.yahoo.com logoEdited Transcript of MCRB earnings conference call or presentation 3-Aug-17 12:00pm GMT
finance.yahoo.com - August 4 at 1:27 AM
americanbankingnews.com logoSeres Therapeutics, Inc. (MCRB) Issues Quarterly Earnings Results, Misses Estimates By $0.05 EPS
www.americanbankingnews.com - August 3 at 8:52 PM
americanbankingnews.com logoSeres Therapeutics, Inc. (NASDAQ:MCRB) PT Set at $20.00 by Canaccord Genuity
www.americanbankingnews.com - August 3 at 7:20 PM
americanbankingnews.com logo Brokerages Expect Seres Therapeutics, Inc. (NASDAQ:MCRB) Will Announce Earnings of -$0.59 Per Share
www.americanbankingnews.com - August 3 at 2:20 PM
finance.yahoo.com logoSeres Therapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 3 at 4:44 AM
finance.yahoo.com logoSeres Therapeutics to Host Second Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2017
finance.yahoo.com - July 28 at 3:38 AM
americanbankingnews.com logoSeres Therapeutics, Inc. (NASDAQ:MCRB) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 24 at 10:54 AM
finance.yahoo.com logoSeres Therapeutics (MCRB) Catches Eye: Stock Gains 9.2%
finance.yahoo.com - July 22 at 6:22 AM
americanbankingnews.com logoSeres Therapeutics, Inc. (NASDAQ:MCRB) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - July 16 at 10:26 AM
americanbankingnews.com logoZacks: Analysts Anticipate Seres Therapeutics, Inc. (MCRB) Will Post Quarterly Sales of $8.00 Million
www.americanbankingnews.com - July 14 at 3:54 PM
americanbankingnews.com logo Brokerages Anticipate Seres Therapeutics, Inc. (MCRB) Will Post Earnings of -$0.57 Per Share
www.americanbankingnews.com - July 12 at 8:44 AM
americanbankingnews.com logoSeres Therapeutics, Inc. (NASDAQ:MCRB) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - July 12 at 7:56 AM
reuters.com logoBRIEF-Seres Therapeutics says size of board increased from 7 to 8
www.reuters.com - July 11 at 1:22 AM
finance.yahoo.com logoSeres Therapeutics Strengthens Board of Directors with Appointment of Willard Dere, M.D., Former Amgen Chief Medical Officer
finance.yahoo.com - July 11 at 1:22 AM
americanbankingnews.com logoSeres Therapeutics, Inc. (MCRB) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - June 27 at 9:26 AM
americanbankingnews.com logoBrokers Issue Forecasts for Seres Therapeutics Inc's FY2018 Earnings (MCRB)
www.americanbankingnews.com - June 26 at 8:26 AM
seekingalpha.com logoSeres Therapeutics: This Time, Success? - Seeking Alpha
seekingalpha.com - June 20 at 3:31 AM
americanbankingnews.com logoSeres Therapeutics, Inc. (MCRB) Expected to Announce Quarterly Sales of $8.00 Million
www.americanbankingnews.com - June 18 at 10:00 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Seres Therapeutics, Inc. (MCRB) to Post -$0.57 Earnings Per Share
www.americanbankingnews.com - June 16 at 8:46 AM
finance.yahoo.com logoSeres Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MCRB-US : June 13, 2017
finance.yahoo.com - June 13 at 6:35 PM
finance.yahoo.com logoSeres Therapeutics' Stock Up as SER-109 Moves to Phase III
finance.yahoo.com - June 13 at 6:35 PM
americanbankingnews.com logoSeres Therapeutics, Inc. (MCRB) Given a $20.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - June 13 at 2:12 PM
nasdaq.com logoXLRN's DART Misses Mark, RGLS Makes Cuts In Pipeline, FDA ... - Nasdaq
www.nasdaq.com - June 13 at 8:04 AM
streetinsider.com logoSeres Therapeutics (MCRB) Commences SER-109 Phase 3 Study in Patients with Multiply Recurrent C. difficile Infection - StreetInsider.com
www.streetinsider.com - June 13 at 8:04 AM
businesswire.com logoSeres Therapeutics Initiates SER-109 Phase 3 Study in Patients with Multiply Recurrent C. difficile Infection - Business Wire (press release)
www.businesswire.com - June 12 at 3:48 PM
finance.yahoo.com logoSeres Therapeutics Initiates SER-109 Phase 3 Study in Patients with Multiply Recurrent C. difficile Infection
finance.yahoo.com - June 12 at 9:08 AM
businesswire.com logoSeres Therapeutics to Present at Goldman Sachs 38th Annual Global Healthcare Conference - Business Wire (press release)
www.businesswire.com - June 6 at 7:10 PM
finance.yahoo.com logoSeres Therapeutics to Present at Goldman Sachs 38th Annual Global Healthcare Conference
finance.yahoo.com - June 6 at 7:10 PM
finance.yahoo.com logoETFs with exposure to Seres Therapeutics, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 7:09 PM
businesswire.com logoSeres Therapeutics Announces Completion of Enrollment for SER-287 Phase 1b Study in Patients with Ulcerative Colitis - Business Wire (press release)
www.businesswire.com - June 5 at 9:27 AM
finance.yahoo.com logoSeres Therapeutics Announces Completion of Enrollment for SER-287 Phase 1b Study in Patients with Ulcerative Colitis
finance.yahoo.com - June 5 at 9:27 AM
finance.yahoo.com logoSeres Therapeutics, Inc. :MCRB-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 7:52 PM

Social

Chart

Seres Therapeutics (MCRB) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff